Navigation Links
Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment
Date:1/7/2009

nificant potential benefits. In particular, ToleroMune should greatly simplify and shorten allergy therapy, while minimizing the risk of the serious and even life-threatening adverse reactions that are associated with current desensitization treatments."

About Circassia

Circassia is a specialty biopharmaceutical company focused on the fields of allergy and critical care. The company has a highly experienced management team with a proven track record in product development and commercialization, and having successfully completed two fundraising rounds is backed by a syndicate of world-class venture capital and institutional investors, including Imperial Innovations, Lansdowne Partners, Goldman Sachs and Invesco Perpetual.

Circassia's anti-allergy products offer potential important clinical benefits compared with existing therapies, and consequently have significant market opportunities. Over 150 million people suffer from allergic rhinitis in the US and Europe and the market for current treatments is approximately $12 billion per year. The prevalence of cat allergies is high, with 1-in-6 Americans and nearly 10% of Europeans suffering from the condition.

Circassia's lead products target allergies utilizing the company's proprietary T-cell epitope desensitization technology, ToleroMune. In addition to ToleroMune's potential therapeutic benefits, its state-of-the-art manufacturing processes fit with changes in the regulatory environment in Europe where authorities are increasingly treating allergen immunotherapies in the same manner as pharmaceuticals, and eliminating the batch-to-batch potency variability that is an intrinsic feature of many currrent products. Circassia is also developing ToleroTrans organ anti-rejection technology, which uses a similar approach to ToleroMune to down-regulate immune responses in transplant patients, and ToleroCare therapy which is designed to dramatically
'/>"/>

SOURCE Circassia Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Circassia Achieves Successful Phase II Clinical Results With Toleromune(R) Anti-Allergy Technology
2. Circassia Initiates Further Phase II Clinical Study of Toleromune(R) Anti-Allergy Technology
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
6. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
7. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
8. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
9. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
10. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
11. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... , April 21, 2015 Workers, compensation ... 5.4 percent decrease in utilization helped offset a 7 ... new data released today by Express Scripts (NASDAQ: ... Workers, Compensation Drug Trend Report discusses the overall pharmacy ... among injured workers. Opioid Management Mitigates ...
(Date:4/21/2015)... , April 21, 2015  TissueGene, Inc. a ... therapies in the field of cell therapy, today ... the position of Chief Operating Officer.  Mr. Newman ... Management & Clinical Operations at ZIOPHARM Oncology, a ... employing novel gene expression, control and cell technologies ...
(Date:4/21/2015)... and PARIS and BURLINGTON, N.C. ... (NYSE: DGX ), the world,s leading ... French National Institute of Health and Medical Research ... initiative they co-founded to provide scientists and laboratory ... BRCA1 and BRCA2 genetic data. The program,s goal ...
Breaking Medicine Technology:Workers' Compensation Prescription Drug Spend Increased 1.9 Percent in 2014, Stabilized by Effective Utilization Management Programs 2Workers' Compensation Prescription Drug Spend Increased 1.9 Percent in 2014, Stabilized by Effective Utilization Management Programs 3Workers' Compensation Prescription Drug Spend Increased 1.9 Percent in 2014, Stabilized by Effective Utilization Management Programs 4TissueGene, Inc. Hires Robert Newman as Chief Operating Officer 2Quest Diagnostics and Inserm Launch Multinational BRCA Gene Datashare Initiative, with LabCorp as First Participant, to Improve the Detection of Inherited Risk of Breast and Ovarian Cancers 2Quest Diagnostics and Inserm Launch Multinational BRCA Gene Datashare Initiative, with LabCorp as First Participant, to Improve the Detection of Inherited Risk of Breast and Ovarian Cancers 3Quest Diagnostics and Inserm Launch Multinational BRCA Gene Datashare Initiative, with LabCorp as First Participant, to Improve the Detection of Inherited Risk of Breast and Ovarian Cancers 4Quest Diagnostics and Inserm Launch Multinational BRCA Gene Datashare Initiative, with LabCorp as First Participant, to Improve the Detection of Inherited Risk of Breast and Ovarian Cancers 5Quest Diagnostics and Inserm Launch Multinational BRCA Gene Datashare Initiative, with LabCorp as First Participant, to Improve the Detection of Inherited Risk of Breast and Ovarian Cancers 6Quest Diagnostics and Inserm Launch Multinational BRCA Gene Datashare Initiative, with LabCorp as First Participant, to Improve the Detection of Inherited Risk of Breast and Ovarian Cancers 7
... HUNTINGTON BEACH, California and AMSTERDAM, ... diagnostics, announced today that,the US Food and Drug Administration ... ages. MammaPrint is the only FDA-cleared,breast cancer recurrence test ... the FDA has issued four clearances for MammaPrint, covering,all ...
... , SAN DIEGO, Dec. 17 Suneva Medical, a ... signed a multi-million dollar line of credit facility with Western ... be used to fund commercial support for Artefill®, the only ... well as to expand Suneva,s Aesthetic Market growth objectives. , ...
Cached Medicine Technology:FDA Broadens Clearance for Agendia's MammaPrint(R) 2Suneva Medical Signs Multi-Million Dollar Line of Credit Agreement with Western Technology Investment 2Suneva Medical Signs Multi-Million Dollar Line of Credit Agreement with Western Technology Investment 3
(Date:4/21/2015)... This year, in recognition of IAM, ... (FIRST) will publish a unique awareness campaign featuring real-life ... the month of May and carry the message, "Be ... The positioning was chosen to encourage the general public ... to help support our mission of educating, inspiring and ...
(Date:4/21/2015)... Approximately 75 million Americans live in areas with ... (EPA). On top of this, consuming alcohol and exposure ... of toxins found in the body. A natural way ... to increase consumption of broccoli. Considered by many as ... – a long-lasting antioxidant – of all cruciferous vegetables. ...
(Date:4/21/2015)... 2015 As a provider of holistic, ... that their rehabilitation strategy, which involves various treatment modalities, ... In an effort to offer hope and encouragement to ... lives, Best Drug Rehabilitation has featured a series of ... successful graduates of their recovery program. , One ...
(Date:4/21/2015)... 21, 2015 Zane Benefits, the leader ... today the publication of a new guide “Health Reimbursement ... changes to the health insurance industry, including how employers ... to question what is permitted when implementing an HRA. ... owners determine which HRAs are compliant this year. ...
(Date:4/21/2015)... Utah (PRWEB) April 21, 2015 Zane ... businesses, announced today its CEO Rick Lindquist has been ... for 2015. , According to Rick Lindquist, “There is ... industry, and Zane Benefits’ small business solutions are at ... recognition provided by Employee Benefit Adviser’s Rising Stars.” , ...
Breaking Medicine News(10 mins):Health News:May is Ichthyosis Awareness Month. Use Your Voice. 2Health News:New Survey Shows Americans Are Cooking the Health Out of Broccoli 2Health News:New Survey Shows Americans Are Cooking the Health Out of Broccoli 3Health News:Best Drug Rehabilitation Graduate Discusses Making Amends and Rebuilding Relationships 2Health News:Zane Benefits’ CEO Named Top 20 Rising Stars 2
... trend towards illicit use of drugs is on the rise ... 400,000 admissions to the emergency department each year. , ... visiting the emergency department of a hospital in South West ... asked to assess the need for treatment with special reference ...
... new evidence shows the high fat, low carb diet promoted ... simply the Atkins' diet) could damage the heart., ... // carbohydrates directly affected the heart's ability to store energy. ... from the Cardiac Metabolism Research Group of Oxford University looked ...
... you know that heart disease is ranked as the ... to a new, simple test called dobutamine stress echocardiography ... // , ,The study has been conducted among ... 75. The study participants underwent a certain type of ...
... have found that drinking and eating sweets may reduce ... produced in the body when the 0person is under ... responsible for increase in weight and obesity. The researchers ... hormone level is reduced causing no increase in weight ...
... Professor Ted Laurence, Lawrence Livermore National Laboratory are studying ... mechanism of protein folding. The new theory on protein ... is incorrectly folded which leads to diseases and the ... of the National Academy of Sciences. , ,The ...
... jailed for life for bludgeoning his friend Stuart Robertson to ... , ,He attacked his friend less than a year ... judge had ordered he be detained indefinitely for another violent ... Glasgow, befriended James Smith while they were both patients at ...
Cached Medicine News:Health News:Heart damage a consequence of Atkins’ Die 2Health News:A Simple Test To Detect Heart Disease In Women Can Be Lifesaving 2Health News:Man Bludgeons Friend, Gets Life Term 2
The SYNCHRON CX7-S workstation offers a broad menu, advanced data management and more. Targeted to the mid-volume lab, the CX7-S is easy to use, easy to maintain and easy to acquire....
... workstation offers a broad menu, ... the mid-size lab that processes ... day. Like all SYNCHRON CX-S ... to use, easy to maintain ...
... for the high-volume lab, the SYNCHRON LX4201 ... performing up to 2,880 tests per hour. ... the SYNCHRON LX4201 with broad menu, speed ... you've come to expect from Beckman Coulter-innovative, ...
... technology to increase laboratory efficiency ... lower costs. It takes the ... features that you will not ... analyzer, including closed tube sampling ...
Medicine Products: